Protara Therapeutics (NASDAQ:TARA) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. began coverage on shares of Protara Therapeutics (NASDAQ:TARA) in a note issued to investors on Wednesday,Benzinga reports. The brokerage set an “overweight” rating and a $27.00 price target on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 339.02% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, January 22nd. Piper Sandler assumed coverage on shares of Protara Therapeutics in a report on Wednesday, January 7th. They set an “overweight” rating and a $24.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $21.50.

Protara Therapeutics Trading Up 3.0%

Protara Therapeutics stock opened at $6.15 on Wednesday. Protara Therapeutics has a 12 month low of $2.77 and a 12 month high of $7.82. The stock has a fifty day simple moving average of $6.05 and a two-hundred day simple moving average of $5.25. The firm has a market cap of $317.52 million, a price-to-earnings ratio of -4.30 and a beta of 1.40.

Institutional Trading of Protara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Los Angeles Capital Management LLC bought a new position in shares of Protara Therapeutics in the second quarter worth about $47,000. Geode Capital Management LLC grew its stake in shares of Protara Therapeutics by 114.7% during the 2nd quarter. Geode Capital Management LLC now owns 744,519 shares of the company’s stock valued at $2,256,000 after acquiring an additional 397,822 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in Protara Therapeutics in the 2nd quarter worth approximately $30,000. Intech Investment Management LLC bought a new stake in Protara Therapeutics during the 2nd quarter worth approximately $49,000. Finally, JPMorgan Chase & Co. bought a new stake in Protara Therapeutics during the 2nd quarter worth approximately $46,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.